000180273 001__ 180273
000180273 005__ 20240229145612.0
000180273 0247_ $$2doi$$a10.3389/fonc.2022.888446
000180273 0247_ $$2pmid$$apmid:35677171
000180273 0247_ $$2pmc$$apmc:PMC9167994
000180273 0247_ $$2altmetric$$aaltmetric:128793745
000180273 037__ $$aDKFZ-2022-01219
000180273 041__ $$aEnglish
000180273 082__ $$a610
000180273 1001_ $$aBhattacharyya, Tapesh$$b0
000180273 245__ $$aEmerging Role of Carbon Ion Radiotherapy in Reirradiation of Recurrent Head and Neck Cancers: What Have We Achieved So Far?
000180273 260__ $$aLausanne$$bFrontiers Media$$c2022
000180273 3367_ $$2DRIVER$$aarticle
000180273 3367_ $$2DataCite$$aOutput Types/Journal article
000180273 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1655127987_17610$$xReview Article
000180273 3367_ $$2BibTeX$$aARTICLE
000180273 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000180273 3367_ $$00$$2EndNote$$aJournal Article
000180273 500__ $$a#LA:E050#
000180273 520__ $$aAdministering reirradiation for the treatment of recurrent head and neck cancers is extremely challenging. These tumors are hypoxic and radioresistant and require escalated radiation doses for adequate control. The obstacle to delivering this escalated dose of radiation to the target is its proximity to critical organs at risk (OARs) and possible development of consequent severe late toxicities. With the emergence of highly sophisticated technologies, intensity-modulated radiotherapy (IMRT) and stereotactic body radiotherapy have shown promising outcomes. Proton beam radiotherapy has been used for locally recurrent head and neck cancers because of its excellent physical dose distribution, exploring sharp Bragg peak properties with negligible entrance and exit doses. To further improve these results, carbon ion radiotherapy (CIRT) has been explored in several countries across Europe and Asia because of its favorable physical properties with minimal entrance and exit doses, sharper lateral penumbra, and much higher and variable relative biological efficacy, which cannot be currently achieved with any other form of radiation. Few studies have described the role of CIRT in recurrent head and neck cancers. In this article, we have discussed the different aspects of carbon ions in reirradiation of recurrent head and neck cancers, including European and Asian experiences, different dose schedules, dose constraints of OARs, outcomes, and toxicities, and a brief comparison with proton beam radiotherapy and IMRT.
000180273 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000180273 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000180273 650_7 $$2Other$$acarbon ion therapy
000180273 650_7 $$2Other$$ahadron therapy beam
000180273 650_7 $$2Other$$aradioresistance
000180273 650_7 $$2Other$$arecurrent head and neck cancer
000180273 650_7 $$2Other$$areirradiation
000180273 7001_ $$aKoto, Masashi$$b1
000180273 7001_ $$aWindisch, Paul$$b2
000180273 7001_ $$aIkawa, Hiroaki$$b3
000180273 7001_ $$aHagiwara, Yasuhito$$b4
000180273 7001_ $$aTsuji, Hiroshi$$b5
000180273 7001_ $$0P:(DE-HGF)0$$aAdeberg, Sebastian$$b6$$eLast author
000180273 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2022.888446$$gVol. 12, p. 888446$$p888446$$tFrontiers in oncology$$v12$$x2234-943X$$y2022
000180273 909CO $$ooai:inrepo02.dkfz.de:180273$$pVDB
000180273 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000180273 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000180273 9141_ $$y2022
000180273 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-27
000180273 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000180273 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000180273 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-27
000180273 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-27
000180273 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2021$$d2022-11-08
000180273 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000180273 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000180273 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T13:25:45Z
000180273 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T13:25:45Z
000180273 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-11T13:25:45Z
000180273 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000180273 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000180273 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000180273 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT ONCOL : 2021$$d2022-11-08
000180273 9202_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000180273 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000180273 980__ $$ajournal
000180273 980__ $$aVDB
000180273 980__ $$aI:(DE-He78)E050-20160331
000180273 980__ $$aUNRESTRICTED